Media stories about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 44.6124374360136 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Eagle Pharmaceuticals (NASDAQ EGRX) opened at 59.82 on Friday. The stock’s 50 day moving average is $57.43 and its 200-day moving average is $71.57. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15. The company has a market cap of $907.41 million, a PE ratio of 10.04 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.18). The company had revenue of $50.10 million for the quarter, compared to the consensus estimate of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.80 EPS. Equities research analysts predict that Eagle Pharmaceuticals will post $3.70 EPS for the current fiscal year.

Eagle Pharmaceuticals announced that its Board of Directors has authorized a share repurchase plan on Wednesday, August 9th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.

A number of analysts have commented on the stock. Piper Jaffray Companies set a $118.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 25th. Mizuho cut their price target on shares of Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 6th. BidaskClub cut shares of Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Royal Bank Of Canada set a $94.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, July 16th. Finally, Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 31st. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $72.50.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Eagle Pharmaceuticals (EGRX) Share Price” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-eagle-pharmaceuticals-egrx-share-price/1612455.html.

In related news, Director Douglas L. Braunstein bought 20,400 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were purchased at an average price of $49.07 per share, with a total value of $1,001,028.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 19.50% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.